CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2021. The put-call ratio across all filers is 0.33 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $162,021 | -4.2% | 3,833 | -3.9% | 0.01% | -12.5% |
| Q4 2023 | $169,134 | +113.9% | 3,989 | +10.1% | 0.01% | +100.0% |
| Q3 2023 | $79,068 | -26.8% | 3,622 | +6.6% | 0.00% | -20.0% |
| Q2 2023 | $108,022 | +34.4% | 3,398 | +3.1% | 0.01% | +25.0% |
| Q1 2023 | $80,365 | -29.0% | 3,295 | -8.1% | 0.00% | -20.0% |
| Q4 2022 | $113,134 | +19.6% | 3,587 | +7.2% | 0.01% | 0.0% |
| Q3 2022 | $94,586 | +6.9% | 3,347 | 0.0% | 0.01% | +25.0% |
| Q2 2022 | $88,495 | -9.8% | 3,347 | +19.4% | 0.00% | 0.0% |
| Q1 2022 | $98,133 | -75.0% | 2,803 | -76.8% | 0.00% | -20.0% |
| Q4 2021 | $391,893 | +13.2% | 12,088 | +3.0% | 0.01% | 0.0% |
| Q3 2021 | $346,124 | +11.2% | 11,733 | -3.5% | 0.01% | +25.0% |
| Q2 2021 | $311,360 | – | 12,153 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 65,679,781 | $2,685,646,245 | 57.02% |
| Twin Securities, Inc. | 416,657 | $17,037,105 | 13.40% |
| Sand Grove Capital Management LLP | 919,023 | $37,578,850 | 10.99% |
| Perceptive Advisors | 10,794,876 | $441,402,480 | 10.63% |
| P SCHOENFELD ASSET MANAGEMENT LP | 796,440 | $32,566,432 | 7.87% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,353,694 | $96,242,547 | 4.60% |
| Avoro Capital Advisors LLC | 7,539,547 | $308,292,077 | 4.11% |
| Melqart Asset Management (UK) Ltd | 1,099,229 | $44,947,474 | 3.72% |
| Paradigm Biocapital Advisors LP | 2,330,508 | $95,294,472 | 3.65% |
| WATER ISLAND CAPITAL LLC | 766,933 | $31,360 | 3.33% |